Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

CCNG2 expression is downregulated in colorectal carcinoma and its clinical significance

Authors: G. G. Sun, J. Zhang, W. N. Hu

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

This study aimed to analyze the expression, clinical significance of cyclin G2 (CCNG2) in colorectal carcinoma, and the biological effect in its cell line by CCNG2 overexpression. Immunohistochemistry and Western blot were used to analyze CCNG2 protein expression in colorectal cancer and to study the influence of the upregulated expression of CCNG2 that might be found on SW480 cell biological effect. We found that the level of CCNG2 protein expression was significantly lower in colorectal cancer tissue than normal tissues (P < 0.05). The level of CCNG2 was correlated with T stages, lymph node metastasis, clinic stage, and histological grade (P < 0.05). Loss of CCNG2 expression correlated significantly with poor overall survival time by Kaplan–Meier analysis (P < 0.05). The result of biological function has shown that SW480 cell-transfected CCNG2 had a lower survival fraction, higher percentage of the G0/G1 phases, and lower CDK2 protein expression compared with SW480 cell-untransfected CCNG2 (P < 0.05).
Literature
1.
Bolocan A, Ion D, Ciocan DN, Paduraru DN. Prognostic and predictive factors in colorectal cancer. Chir (Bucur). 2012;107:555–63.
2.
Dimofte G, Tarcoveanu E, Taraşi M, Panait C, Lozneanu G, Nicolescu S, et al. Mean number of lymph nodes in colonic cancer specimen: possible quality control index for surgical performance. Chir (Bucur). 2011;106:759–64.
3.
Ahmed S, Al-Saigh S, Matthews J. FOXA1 is essential for aryl hydrocarbon receptor-dependent regulation of cyclin G2. Mol Cancer Res. 2012;10:636–48.PubMedCrossRef
4.
Bates S, Rowan S, Vousden KH. Characterization of human cyclin G1 and G2: DNA damage inducible genes. Oneogene. 1996;13:1103–9.
5.
Horne MC, Goolsby GL, Donaldson KL, Tran D, Neubauer M, Wahl AF. Cyclin G1 and cyclinG2 comprise a new family of cyclins with contrasting cycle-regulated expression. J Biol Chem. 1996;271:6050–61.PubMedCrossRef
6.
Kim Y, Shintani S, Kohno Y, Zhang R, Wong DT. Cyclin G2 dysregulation in human oral cancer. Cancer Res. 2004;64:8980–6.PubMedCrossRef
7.
Cui XF, Liu AJ, Xu ZM. Expression of Cyclin G2 and its clinical significance in laryngeal squamouse cell carcinorna. J Clin Torhinolaryngol. 2009;23:277–9.
8.
Shan G, Shan SG, Zhang XB. Expression and clinical significance of cyclin G1 and cyelinG2 in transitional cell carcinoma of bladder. Chin J Histochem Cytochmistry. 2009;18:268–72.
9.
Choi MG, Noh JH, An JY, Hong SK, Park SB, Baik YH, et al. Expression levels of cyclinG2, but not cyclin E, correlate with gastric progression. J Surg Res. 2009;157:168–74.PubMedCrossRef
10.
Shi W, Yu KR, Wu GY, Zhang H. Expression of CCNG2 in gastric carcinorna and its relationship with prognosis. Chin J Cell Boi. 2011;33:994–7.
11.
Song YL, Hu GH. CyclinG2: correlation with head and neck neoplasms. Intl J Otolaryngol-Head Neck Surg. 2006;30:8–11.
12.
Le XF, Arachehige-Don AS, Mao W, Horne MC, Bast Jr RC. Roles of human epidermal growth factor receptor 2, c-Jun NH2-terminal kinase, PhosPhoinositide 3-kinase, and P7056 kinase pathways in regulation of cyclinG2 expression in human breast cancer cells. Mol Cancer Ther. 2007;6:2843–57.PubMedCrossRef
13.
Martinez-Gac L, Marqués M, García Z, Campanero MR, Carrera AC. Control of cyclinG2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. Mol Cell Biol. 2004;4:2181–9.CrossRef
14.
Chen J, Yusuf L, Andersen HM, Fruman DA. FOXO transcription factors cooperate withδEF1 to activate growth suppressive genes in B-lymphocytes. J Immunol. 2006;76:2711–21.
15.
Xu G, Bernaudo S, Fu G, Lee DY, Yang BB, Peng C. CyclinG2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7. Mol Biol Cell. 2008;9:4968–79.CrossRef
16.
Cellai C, Laurenzana A, Bianchi E, Sdelci S, Manfredini R, Vannucchi AM, et al. Mechanistic insight intoWEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Exp Hematol. 2009;7:1176–85.CrossRef
17.
van Duijn PW, Ziel-van der Made AC, van der Korput JA, Trapman J. PTEN-mediated Gl cell-cycle arrest in LNCaP prostate cancer cells is associated with altered expression of cell-cycle regulators. Prostate. 2010;70:135–46.PubMed
18.
Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, et al. Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J Biol Chem. 1997;272:12650–61.PubMedCrossRef
19.
Bennin DA, Don AS, Brake T, McKenzie JL, Rosenbaum H, Ortiz L, et al. Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B' subunits in active complexes and induces nuclear aberrations and a Gl/S phase cell cycle arrst. J Biol Chem. 2002;2779:27449–67.CrossRef
20.
Arachchige Don AS, Dallapiazza RF, Bennin DA, Brake T, Cowan CE, Horne MC. CyclinG2 is a centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a P53-dependent cell cycle arrest. Exp Cell Res. 2006;312:4181–204.PubMedCentralPubMedCrossRef
Metadata
Title
CCNG2 expression is downregulated in colorectal carcinoma and its clinical significance
Authors
G. G. Sun
J. Zhang
W. N. Hu
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1440-5

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

Detection and clinical significance of genes in primary gastrointestinal MALT lymphoma

Research Article

Meta-analysis: eating frequency and risk of colorectal cancer

Research Article

Association between ERCC1 C8092A and ERCC2 K751Q polymorphisms and risk of adult glioma: a meta-analysis

Research Article

The volume and duration of wound drainage are independent prognostic factors for breast cancer

Research Article

Study on the association between the Arg194Trp polymorphism in the XRCC1 gene and the risk of hematological malignancies

Research Article

Tetra-arsenic tetra-sulfide (As4S4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits